GlassScriptPhysician profile
Beena Rajagopal
NPI 1700335791
$5,925.82
in general payments reported to CMS, 2019-2025
29 companies · $3,700 in 2025
The $3,700 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $334 · 2024: $1,891 · 2025: $3,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,827 · Education: $98.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,826.94 |
| Education | $98.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.51 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $886.32 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $693.01 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $670.05 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $454.06 | 2024-2025 | |
| Pfizer INC. | $410.24 | 2024-2025 | |
| Genzyme Corporation | $323.89 | 2023-2025 | |
| Lilly USA, LLC | $259.76 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $207.53 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $133.74 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $100.61 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $95.93 | 2024 | |
| Alnylam Pharmaceuticals INC. | $93.61 | 2024-2025 | Givlaari |
| Neuraxis, INC. | $87.50 | 2025 | |
| Madrigal Pharmaceuticals | $87.04 | 2025 | Rezdiffra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $70.29 | 2024 | Sucraid |
| Aimmune Therapeutics, INC. | $69.60 | 2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $49.01 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $46.93 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.88 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $29.55 | 2024 | Voquezna |
| Celgene Corporation | $27.22 | 2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $23.45 | 2025 | Rebyota |
| Celltrion USA INC. | $19.88 | 2024 | Zymfentra |
| Novo Nordisk INC | $16.19 | 2024 | Saxenda, Wegovy |
| Orphalan INC | $15.06 | 2025 | Cuvrior |
| Braintree Laboratories, INC. | $14.95 | 2024 | Sutab |
| Currax Pharmaceuticals LLC | $13.88 | 2025 | Contrave |
| Medtronic, INC. | $13.13 | 2024 | Signia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beena Rajagopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.